National Toxicology Program Requests Data on 11 Chemicals

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

RESEARCH TRIANGLE PARK, NC--The National Toxicology Program has requested public input on 11 chemicals recommended for absorption, toxicity, or carcinogenicity studies. It seeks information from completed or ongoing studies, and information on planned studies, as well as current production data, human exposure information, use patterns, and environmental occurrences.

RESEARCH TRIANGLE PARK, NC--The National Toxicology Program has requested public input on 11 chemicals recommended for absorption, toxicity, or carcinogenicity studies. It seeks information from completed or ongoing studies, and information on planned studies, as well as current production data, human exposure information, use patterns, and environmental occurrences.

The compounds include bixin and fenchone, natural products with widespread human exposure; diethylamine, found in some foods; dihydroxyacetone, a component of tanning compounds; isopropylamine, a natural product in foods; pulegone, a flavoring; menthofu-ran, a metabolite of pulegone; and alpha-solanine, a known human toxicant.

Also, alpha-thujone a component of food flavoring additives; triethylamine, a workplace contaminant, and trigonelline, a plant hormone with widespread human exposure through diet.

Information may be submitted until July 27 to William Eastin, NIEHS/NTP, P.O. Box 12233, Research Triangle Park, NC 27709; Fax: 919-541-3687; e-mail: Eastin@NIEHS.

Recent Videos
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
4 experts in this video
4 experts in this video
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
7 experts are featured in this series.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
Related Content